Novartis Investigative Site

Cheongju-si, North Chungcheong 28644

0 studies enrolling now · 13 studies all time

What they study most

Acute Heart Failure, Acute Myocardial Infarction, Asthma, Atherosclerotic Cardiovascular Disease, Diabetes Mellitus and Heart Failure, Early Breast Cancer, Heart Failure With Preserved Ejection Fraction, IgA Nephropathy, Non-Small Cell Lung Cancer, Primary IgA Nephropathy

Studies at this site

• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy — Running, not enrolling
• Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease — Running, not enrolling
• A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer — Running, not enrolling
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients — Completed
• Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A — Stopped early
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction — Completed
• A Multicenter Randomized 52 Week Treatment Double-blind, Triple Dummy Parallel Group Study to Assess the Efficacy and Safety of QMF149 Compared to Mometasone Furoate in Participants With Asthma — Completed
• A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure — Stopped early
• Global Non-interventional Heart Failure Disease Registry — Stopped early
• Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma — Completed
• Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201 — Stopped early
• A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients — Completed